Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Anticancer drug dosing--pharmacogenomic biomarkers or body surface area?].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke - 19 Apr 2007

Lehne Gustav, Bjørheim Jens, Saeter Gunnar

Abstract excerpt

BACKGROUND: Chemotherapeutic treatment regimes are established for most cancer forms. In general, these substances have extremely narrow therapeutic windows, which render cancer patients vulnerable to over- and underdosing. Individual drug dosing is currently based on the patients' body surface area. This practice is an extrapolation from animal studies. Recent advances in molecular medicine raise the question of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Genetic Variation

Share to Neoplasms

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Prognosis

Source

Identifiers

PMID: 17457389

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Anticancer drug dosing--pharmacogenomic biomarkers or body surface area?].PMID 17457389Read ↗

Part 1: background, methodology, and clinical adoption of pharmacogenetics.Semantic proximity Read ↗

Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.Semantic proximity Read ↗

Phenotype versus genotype to optimize cancer dosing in the clinical setting-focus on 5-fluorouracil and tyrosine kinase inhibitors.Semantic proximity Read ↗

[Pharmacogenetics of anticancer drugs].Semantic proximity Read ↗

Pharmacogenetics of Drugs Used in the Treatment of CancersSemantic proximity Read ↗

Pharmacogenetics and pharmacogenomics of anticancer agents.Semantic proximity Read ↗

Pharmacogenetics in cancer chemotherapy: balancing toxicity and response.Semantic proximity Read ↗

Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy.Semantic proximity Read ↗

Application of pharmacogenetics in oncologySemantic proximity Read ↗

Cancer pharmacogeneticsSemantic proximity Read ↗

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.Semantic proximity Read ↗

Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.